CTLA4 and non-small cell lung carcinoma: Anti-PD-1/PD-L1 inhibitor monotherapies and combination therapies with cytotoxic chemotherapy (with/without anti-angiogenic agents) and/or anti-CTLA-4 inhibitors are now standard front-line therapies for advanced-stage NSCLC without a targetable driver mutation [1].